The association between PAI-1-675 4G/5G polymorphism and type 2 diabetes mellitus

被引：1
|
作者：
Chen, L. [1 ]
Li, S-Y. [1 ]
Liu, M. [1 ]
机构：
[1] Tianjin Gong An Hosp, Dept Endocrinol, Tianjin 300042, Peoples R China
来源：
CELLULAR AND MOLECULAR BIOLOGY | 2017年 / 63卷 / 07期
关键词：
Type 2 diabetes mellitus; PAI-1; Polymorphism; Association; PLASMINOGEN-ACTIVATOR INHIBITOR-1; GENE; POPULATION; RISK;
D O I：
10.14715/cmb/2017.63.7.11
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
In this study, we aimed to analyze the association between plasminogen activator inhibitor 1 (PAI-1)-675 4G/5G polymorphism and type 2 diabetes mellitus (T2DM) risk. We included in 187 T2DM patients and 186 heathy controls between 2014 and 2017 from Tianjin Gong An Hospital, China. All patients and controls were ethnically Chinese Han population. The primers and polymerase chain reaction (PCR) conditions were performed. Results from this case-control study suggested that PAI-1-675 4G/5G polymorphism was not associated with T2DM risk in four genetic models. Additionally, PAI-1-675 4G/5G polymorphism was not associated with clinical and laboratory characteristics, such as age, gender, body mass index, systolic blood pressure, diastolic blood pressure, total cholesterol, triglycerides, and HbA1c. In conclusion, this case-control study suggested that PAI-1-675 4G/5G polymorphism was not associated with T2DM risk in this population.
引用
收藏
页码：66 / 68
页数：3
相关论文
共 50 条
  • [31] Association between the PAI-1 4G/5G Gene Polymorphism and the Risk of Systemic Lupus Erythematosus/Lupus Nephritis
    Li, Wei
    Mao, Song
    Wu, Liangxia
    Shi, Wenjing
    Zhang, Jianhua
    Wang, Zhong
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2019, 29 (01): : 85 - 94
  • [32] Association between PAI-1 4G/5G polymorphism and diabetic nephropathy: a meta-analysis in the Chinese population
    Wen-feng Gao
    Ying-bo Guo
    Yu Bai
    Xin-yu Ding
    Yong-ji Yan
    Zhen-qi Wu
    International Urology and Nephrology, 2016, 48 : 1483 - 1489
  • [33] An alternative method for PAI-1 promoter polymorphism (4G/5G) typing
    Margaglione, M
    Grandone, E
    Cappucci, G
    Colaizzo, D
    Giuliani, N
    Vecchione, G
    dAddedda, M
    DiMinno, G
    THROMBOSIS AND HAEMOSTASIS, 1997, 77 (03) : 605 - 606
  • [34] Presence of type 2 diabetes significantly modulates the cardiovascular risk conferred by the plasminogen activator inhibitor-1-675 5G/4G polymorphism
    Muendlein, Axel
    Saely, Christoph H.
    Marte, Thomas
    Schmid, Fabian
    Koch, Lorena
    Rein, Philipp
    Aczel, Stefan
    Langer, Peter
    Drexel, Heinz
    DIABETES, 2007, 56 : A180 - A180
  • [35] PAI-1 4G/5G POLYMORPHISM IN PATIENTS WITH SPLANCHNIC VEIN THROMBOSIS
    Kumar, Narender
    Kollabathula, Arpitha
    Jamwal, Manu
    Ahluwalia, Jasmina
    Das, Reena
    Varma, Neelam
    Rana, Surinder K.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2019, 41 : 95 - 95
  • [36] Presence of type 2 diabetes significantly modulates the cardiovascular risk conferred by the plasminogen activator inhibitor-1-675 5G/4G polymorphism
    Muendlein, Axel
    Seely, Christoph H.
    Marle, Thomas
    Schmid, Fabian
    Koch, Lorena
    Rein, Philipp
    Aczel, Stefan
    Langer, Peter
    Drexel, Heinz
    CIRCULATION, 2007, 116 (16) : 857 - 857
  • [37] Presence of type 2 diabetes significantly modulates the cardiovascular risk conferred by the plasminogen activator inhibitor-1-675 5G/4G polymorphism
    Muendlein, A.
    Saely, C. H.
    Marte, T.
    Schmid, F.
    Koch, L.
    Aczel, S.
    Langer, P.
    Drexel, H.
    EUROPEAN HEART JOURNAL, 2007, 28 : 456 - 456
  • [38] The effect of plasminogen activator inhibitor-1-675 4G/5G polymorphism on PAI-1 gene expression and adipocyte differentiation
    Demiralp, Duygu Ozel
    Aktas, Huseyin
    Akar, Nejat
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2008, 14 (04) : 438 - 446
  • [39] Significant impact of the presence of type 2 diabetes on the cardiovascular risk conferred by the plasminogen activator inhibitor-1-675 5G/4G polymorphism
    Muendlein, A.
    Saely, C. H.
    Marte, T.
    Rein, P.
    Schmid, F.
    Koch, L.
    Langer, P.
    Aczel, S.
    Drexel, H.
    DIABETOLOGIA, 2007, 50 : S149 - S149
  • [40] PRESENCE OF TYPE 2 DIABETES SIGNIFICANTLY MODULATES THE CARDIOVASCULAR RISK CONFERRED BY THE PLASMINOGEN ACTIVATOR INHIBITOR-1-675 5G/4G POLYMORPHISM
    Saely, C. H.
    Muendlein, A.
    Vonbank, A.
    Aczel, S.
    Marte, T.
    Rein, P.
    Risch, L.
    Drexel, H.
    ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 3 - 3
12345